Neurology Xagena
In patients with Alzheimer's disease ( AD ), the relationship between cognitive and functional progression is not fully understood; however, functional decline has been postulated to follow cognitive ...
The Food and Drug Administration ( FDA ) has approved Duopa ( Carbidopa and Levodopa ) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. Duopa is ...
In a 6-month double-blind, placebo-controlled study of Parkinson's disease patients with motor fluctuations, Safinamide ( Xadago ) 50 and 100 mg/die significantly increased ON-time without increasing ...
Previous reports indicate an association between Epstein-Barr virus ( EBV ) antibody levels and multiple sclerosis ( MS ) disease activity, but the results have been conflicting. The objective of a ...
Psychiatric disorders are known to be prevalent in multiple sclerosis ( MS ). The objective of this paper was to study comorbidity between multiple sclerosis and bipolar disorder, schizophrenia and de ...
Statin use during hospitalization is associated with improved survival and a better discharge disposition among patients with ischemic stroke. It is unclear whether inpatient statin use has a similar ...
The benefit of statins in patients with acute aneurysmal subarachnoid haemorrhage is unclear. A study aimed to determine whether Simvastatin ( Zocor ) 40 mg could improve the long-term outcome in pati ...
Subcutaneous Pegylated interferon ( Peginterferon ) beta-1a ( Plegridy ) has been developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line ...
Traumatic brain injury ( TBI ) is a major cause of death and disability worldwide. Progesterone has been shown to improve neurologic outcome in multiple experimental models and two early-phase trials ...
Levodopa is effective for the motor symptoms of Parkinson's disease ( PD ), but is associated with motor fluctuations and dyskinesia. Many patients require add-on therapy to improve motor fluctuations ...
The baseline severity of cervical dystonia is shown in short segments, along with outcomes after 6 months of pallidal neurostimulation in three study participants. Cervical dystonia is managed mainly ...
Patients who develop relapsing-remitting multiple sclerosis ( MS ) present with a first clinical demyelinating event. In this double-blind, multicentre, randomised, phase 3 study, ORACLE MS, researche ...
No available treatments slow or halt progression of multiple system atrophy, which is a rare, progressive, fatal neurological disorder. In a mouse model of multiple system atrophy, Rifampicin ( Rifadi ...
Teriflunomide ( Aubagio ) is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting multiple sclerosis. Researchers have assessed the efficacy and safety of Teriflunomi ...
Whether initial treatment for Parkinson's disease should consist of Levodopa, dopamine agonists, or monoamine oxidase type B inhibitors ( MAOBI ) is uncertain. Researchers aimed to establish which o ...
The Committee for Medicinal Products for Human Use ( CHMP ) has recommended that the European Commission approve the use of Xadago ( Safinamide ) as add-on to L-dopa alone or in combination with dopam ...
The lack of prospective trial data comparing certain multiple sclerosis therapies could be addressed with observational research. Researchers have investigated outcomes of Natalizumab ( Tysabri ) v ...
A study has evaluated the efficacy and safety of subcutaneous Peginterferon beta-1a ( Plegridy ) over 2 years in patients with relapsing-remitting multiple sclerosis in the ADVANCE study. Patients ...
Up to 70% of Parkinson’s disease ( PD ) patients experience sleep problems that negatively impact their quality of life. Some patients have disturbed sleep/wake patterns such as difficulty falling asl ...
Deep brain stimulation ( DBS ) has become a well-recognized nonpharmacologic treatment that improves motor symptoms of patients with early and advanced Parkinson’s disease. Evidence now indicates th ...
Frontotemporal dementia ( FTD ) is a complex disorder characterised by a broad range of clinical manifestations, differential pathological signatures, and genetic variability. Mutations in three genes ...
Progesterone has been associated with robust positive effects in animal models of traumatic brain injury ( TBI ) and with clinical benefits in two phase 2 randomized, controlled trials. Researchers ...
The FDA ( Food and Drug Administration ) has approved Lemtrada ( Alemtuzumab ) for the treatment of patients with relapsing forms of multiple sclerosis ( MS ). Because of its safety profile, the use o ...
Migraine remains poorly treated, with few effective preventive drugs available. Researchers assessed the safety and efficacy of LY2951742, a fully humanised monoclonal antibody to CGRP ( calcitonin ge ...
It is known that the risk of stroke in patients with traumatic brain injury might be increased. However, the relationship between mild traumatic brain injury and ischemic stroke has never been establi ...
Duchenne muscular dystrophy is caused by dystrophin deficiency and muscle deterioration and preferentially affects boys. Antisense-oligonucleotide-induced exon skipping allows synthesis of partially f ...
Phase IIa clinical trial data on ATL1102 were published in the medical journal Neurology. The article highlights the successful outcomes of the randomised, double-blind, placebo-controlled study in 77 ...
In preclinical studies, Davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy ( PSP ) is linked to tau pathology, Davunetide could be a trea ...
Teriflunomide ( Aubagio ) is an oral disease-modifying therapy approved for treatment of relapsing or relapsing–remitting multiple sclerosis. Researchers aimed to provide further evidence for the sa ...
The evaluation of therapeutic choices is needed after 24 doses of Natalizumab ( Tysabri ) in patients with multiple sclerosis ( MS ). A study has evaluated the effect of therapeutic choices on the me ...
No reliable treatment options are known for progressive multifocal leukoencephalopathy with underlying immunodeficiency. Researchers have described successful compassionate use of in a patient with ...
Five-year results from the ENDORSE phase 3 extension study have shown Dimethyl fumarate ( Tecfidera ) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting ...
In a 6-month double-blind, placebo-controlled study of Parkinson's disease patients with motor fluctuations, Safinamide 50 and 100 mg/d significantly increased ON-time without increasing dyskinesia. ...
Many of those who are genetically predisposed to develop atrial fibrillation, which dramatically raises the risk of stroke, can be identified with a blood test. This is shown by new research from Lund ...
Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented at the European Committee for Research and Treatment in Multiple Sclerosis ...
Increasing evidence suggests that seizures and status epilepticus can be immune-mediated. Researchers aimed to describe the clinical features of a new epileptic disorder, and to establish the target ...
A follow-up study of patients with Parkinson’s disease ( PD ) who participated in an earlier proof of concept clinical trial using Exenatide showed that improvements persisted twelve months after disc ...
As preclinical Alzheimer's disease becomes a target for therapeutic intervention, the overlap between imaging abnormalities associated with typical ageing and those associated with Alzheimer's disease ...
The full results from the phase 3 DECIDE clinical trial have shown a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis ( RRMS ) w ...
The phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis ( RMS ) met the primary endpoint, reduction in MRI brain lesion activity. ...
The prognostic significance of age and continuous positive airway pressure ( CPAP ) therapy on cardiovascular disease in patients with sleep apnoea has not been assessed previously. Using nationwid ...
It is studied the applicability of the Acute Physiology and Chronic Health Evaluation II ( APACHE II ) and Simplified Acute Physiology Score II ( SAPS II ) in patients admitted to the intensive care u ...
The FDA-approved trial, A Phase 1, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Scler ...
A study has evaluated the ability of Lithium carbonate and Valproate cotreatment to modify the survival rate and functional score of patients with definite sporadic amyotrophic lateral sclerosis ( ALS ...
In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received Daclizumab high-yield process ( HYP ) for 52 weeks. The primary aim of the SELECTION extension st ...
Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. Researchers have assessed whether uric acid therapy would improve functional outcomes at 90 days in patients ...
Parkinson's disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson's disease. Researchers have assessed safety and efficacy of Pimavans ...
A retrospective cohort study using data from a large scale, comprehensive population based state-wide stroke registry in Germany, has assessed the time dependent effectiveness of thrombolytic therapy ...
Although the benefit of reducing blood pressure for primary and secondary prevention of stroke has been established, the effect of antihypertensive treatment in patients with acute ischemic stroke is ...
Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. The ...
2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati
